title: [New oral anticoagulants in primary care: The general practitioner's point of view].
abstract: The assessment of new anticoagulants benefits is based on the assessment of thromboembolism and bleeding risks, referring when possible to CHA2DS2-VASc and HAS-BLED scores. The management of patients treated with new anticoagulants includes a clinical assessment and the annual measure of the creatinine clearance (three times per year in some particular cases). New anticoagulants make hemostasis tests not reliable. The general practitioner has a role in preventing interactions and reporting potential adverse drug reactions. The context of uncertainty about the risk/benefit ratio of new anticoagulants emphasizes the need to integrate the values of the patient in treatment decisions.
authors.affiliation: Université Jean-Monnet, département de médecine générale, 42023 Saint-Étienne, France; Université Jean-Monnet, groupe de recherche sur la thrombose, EA3065, 42023 Saint-Étienne, France; Inserm/DGOS, CIE3, 42055 Saint-Étienne, France. Electronic address: paul.frappe@univ-st-etienne.fr.
authors.forename: Paul
authors.initials: P
authors.lastname: Frappé
authors.forename: Sandra
authors.initials: S
authors.lastname: Liébart
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D058006:General Practice; D006801:Humans; D010818:Practice Patterns, Physicians'; D011320:Primary Health Care
chemical_list: D000925:Anticoagulants